bioRxiv · 10.1101/2024.05.13.593856
Kynurenine monooxygenase blockade reduces endometriosis-like lesions, improves visceral hyperalgia, and rescues mice from a negative behavioural phenotype in experimental endometriosis
Abstract
Endometriosis is a common and debilitating neuro-inflammatory disorder that is associated with chronic pain. Definitive diagnosis is based on the presence of endometrial-like tissue (lesions) in sites outside the uterus. Kynurenine monooxygenase (KMO) is a mitochondrial enzyme of tryptophan metabolism that regulates inflammation and immunity. Here, we show that KMO is expressed in epithelial cells in human endometriosis tissue lesions and in corresponding lesions in a mouse model of endometriosis. In mice, oral treatment with the potent KMO inhibitor KNS898 induced a biochemical state of KMO blockade with accumulation of kynurenine, diversion to kynurenic acid and ablation of 3-hydroxykynurenine production. In the mouse model of endometriosis, KMO inhibition improved histological outcomes and endometriosis pain-like behaviours, even when KNS898 treatment commenced one week after initiation of lesions. Taken together, these results suggest that KMO blockade is a promising new non-hormonal therapeutic modality for endometriosis.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Higgins, B., Simitsidellis, I., Zheng, X., Collins, F., Homer, N., Denham, S., Simpson, J., Millar, M., Boswell, L., Lee, H. Y., Kim, Y. G., Park, K. H., Park, L. C., Sweeney, P. J., Feraille, G., Taddei, A., Chagras, D., Alvarez, T., Webster, S. P., Horne, A. W., Saunders, P. T., Mole, D. J.. 2024-05-15. Kynurenine monooxygenase blockade reduces endometriosis-like lesions, improves visceral hyperalgia, and rescues mice from a negative behavioural phenotype in experimental endometriosis. https://doi.org/10.1101/2024.05.13.593856
Cite the original work for its findings. Save a collection to share your selection of sources.